Clinical trials: Locally Advanced Head and Neck Carcinoma
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Squamous Cell Carcinoma, Carcinoma of Head/Neck
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects…
- Trial name
- NCT00139230
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumours, Endometrial Cancer
A Phase 1 Study of [225Ac]-FPI-1434 Injection
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic…
- Conditions
- Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer
- Trial name
- NCT03746431
- Testing
- [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Squamous Cell Carcinoma of Head and Neck
Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy.
- Trial name
- NDURE2 (NCT04030130)
- Testing
- NDURE
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Medical University of South Carolina
Esophageal Squamous Cell Carcinoma (ESCC)
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
This study is a prospective, randomized controlled, phase III multicenter trial. Its objectives are to explore the stratified application of consolidation immunotherapy after chemoimmunotherapy induction plus concurrent…
- Trial name
- NCT07246330
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result in higher treatment related toxicity and…
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
- Trial name
- AGMT_HNO_PN (NCT02236936)
- Testing
- Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab
- Where
- 7 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma patients
- Trial name
- NCT05302011
- Testing
- Pembrolizumab, Carboplatin or Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local…
- Trial name
- NCT00121628
- Testing
- AMG 706
- Volunteers
- 184 people
- Sponsor
- Amgen
Esophageal Cancer
PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PNU-93914 in treating patients who have locally…
- Trial name
- NCT00016900
- Testing
- liposomal paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may…
- Trial name
- NCT00956007
- Testing
- cetuximab, intensity-modulated radiation therapy
- Where
- 264 sites in United States, Canada and 2 more
- Volunteers
- 702 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Locally Advanced Head and Neck Cancer
A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
The primary endpoint in this study is to investigate if there is a difference in overall survival in patients with locally advanced head and neck cancer, randomized to either radiotherapy and cetuximab or radiotherapy and…
- Trial name
- ARTSCANIII (NCT01969877)
- Testing
- cetuximab, cisplatin
- Where
- 9 sites in Sweden
- Volunteers
- 298 people
- Sponsor
- Lund University Hospital
Head and Neck Cancer
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
The phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma…
- Trial name
- ORCA-2 (NCT02308072)
- Testing
- Olaparib, Cisplatin, IMRT
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Nausea, Vomiting
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
This study sought to investigate the efficacy and safety of a three-drug combination antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention of chemoradiotherapy-induced nausea and vomiting…
- Conditions
- Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect
- Trial name
- NCT05202275
- Testing
- Olanzapine
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Surgical resection is currently the major treatment for esophageal carcinoma while disease progression still occurred in most cases within 3 years.
- Trial name
- NCT04390958
- Testing
- nab-paclitaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.